X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CIPLA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CIPLA SUN PHARMA/
CIPLA
 
P/E (TTM) x 42.3 34.4 122.9% View Chart
P/BV x 3.3 3.0 109.4% View Chart
Dividend Yield % 0.4 0.6 68.1%  

Financials

 SUN PHARMA   CIPLA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
CIPLA
Mar-18
SUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs701663 105.7%   
Low Rs433479 90.4%   
Sales per share (Unadj.) Rs110.4189.0 58.4%  
Earnings per share (Unadj.) Rs11.017.6 62.4%  
Cash flow per share (Unadj.) Rs17.234.0 50.6%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.40.5 67.2%  
Book value per share (Unadj.) Rs158.8176.7 89.9%  
Shares outstanding (eoy) m2,399.26805.12 298.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.0 170.0%   
Avg P/E ratio x51.632.5 159.1%  
P/CF ratio (eoy) x32.916.8 196.1%  
Price / Book Value ratio x3.63.2 110.5%  
Dividend payout %18.217.1 106.9%   
Avg Mkt Cap Rs m1,360,021459,724 295.8%   
No. of employees `00017.823.6 75.3%   
Total wages/salary Rs m53,67126,901 199.5%   
Avg. sales/employee Rs Th14,890.96,446.1 231.0%   
Avg. wages/employee Rs Th3,017.11,139.4 264.8%   
Avg. net profit/employee Rs Th1,480.6600.0 246.8%   
INCOME DATA
Net Sales Rs m264,895152,193 174.1%  
Other income Rs m8,3883,577 234.5%   
Total revenues Rs m273,282155,769 175.4%   
Gross profit Rs m56,08128,264 198.4%  
Depreciation Rs m14,99813,228 113.4%   
Interest Rs m5,1761,142 453.1%   
Profit before tax Rs m44,29517,470 253.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m-9,505-775 1,226.1%   
Tax Rs m8,4522,501 337.9%   
Profit after tax Rs m26,33814,166 185.9%  
Gross profit margin %21.218.6 114.0%  
Effective tax rate %19.114.3 133.3%   
Net profit margin %9.99.3 106.8%  
BALANCE SHEET DATA
Current assets Rs m316,359108,141 292.5%   
Current liabilities Rs m198,64338,322 518.4%   
Net working cap to sales %44.445.9 96.9%  
Current ratio x1.62.8 56.4%  
Inventory Days Days9597 97.7%  
Debtors Days Days10874 144.7%  
Net fixed assets Rs m213,178109,411 194.8%   
Share capital Rs m2,3991,610 149.0%   
"Free" reserves Rs m378,606140,682 269.1%   
Net worth Rs m381,006142,292 267.8%   
Long term debt Rs m17,72136,621 48.4%   
Total assets Rs m643,028228,606 281.3%  
Interest coverage x9.616.3 58.7%   
Debt to equity ratio x00.3 18.1%  
Sales to assets ratio x0.40.7 61.9%   
Return on assets %4.96.7 73.2%  
Return on equity %6.910.0 69.4%  
Return on capital %10.010.0 100.7%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81651,691 79.0%   
Fx outflow Rs m30,14321,033 143.3%   
Net fx Rs m10,67330,658 34.8%   
CASH FLOW
From Operations Rs m39,07214,628 267.1%  
From Investments Rs m-33,708-8,540 394.7%  
From Financial Activity Rs m-15,393-3,855 399.3%  
Net Cashflow Rs m-7,3592,431 -302.7%  

Share Holding

Indian Promoters % 63.7 16.0 398.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.1 12.2 42.0%  
FIIs % 23.0 23.7 97.0%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.3 26.2 31.7%  
Shareholders   133,026 161,166 82.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ELDER PHARMA  FDC LTD.  ORCHID PHARMA LTD  DISHMAN PHARMA  TTK HEALTHCARE  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - WYETH LTD COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS